Product Code: RP-ID-10084541 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10084541
Market Overview:
Patient-Controlled Injectors Market Analysis by Product (Electronic Wearable Injector, Mechanical Wearable Injector, and Infusion Pumps); by Application (Cancer Treatment, Auto Immune Treatment, and Blood Disorder Treatment); and by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Mail Order Pharmacies)-Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Definition of Patient-Controlled Injectors
The innovation in injectable administration is the patient-controlled injector. The medical gadget delivers comfort and ease compared to conventional medical equipment, which helps it meet patients' unmet needs. Additionally, the ergonomically designed gadget aids patients in enhancing self-care, making it simpler for patients to efficiently handle & dispense the medications at a set interval. In addition, the medical gadget serves as a subcutaneous drug delivery instrument that adheres to the patient's body and aids in administering large doses of medication.
Global Patient-Controlled Injectors Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~13% |
|
Base Year Market Size (2022) |
~ USD 3 Billion |
|
Forecast Year Market Size (2033) |
~ USD 8 Billion |
|
Regional Scope |
|
Global Patient-Controlled Injectors Market Highlights Over 2023-2033
The global patient-controlled injectors market is estimated to garner a revenue of USD 8 billion by the end of 2033 by growing at CAGR of ~13% over the forecast period, i.e., 2023-2033. Further, the market generated a revenue of USD 3 billion in the year 2022. The growth of the market can primarily be attributed to increase in frequency of chronic conditions. As a result of growing urbanization and rise in middle class people are preferring more sedentary life which had now pushed the obesity rate increasing the risk of diseases such as diabetes. According to the National Library of Medicine, it was expected that the chronic disease frequency will rise by 57% by 2020.
GET A SAMPLE COPY OF THIS REPORT
The demand for injector went up during Covid19 pandemic. There was a surge in infected patient by caused of covid19 virus which led to the shift from hospital-based treatment to home-based treatment. Cancer or any other chronic disease patients will able to self-treat themselves at home with the help of injectors. Technology advancement will be another factor responsible for the growth in the market for patient-controlled injectors. People preference for advanced drug delivery solution that offers great comforts is increasing.
With the advancement in medical technology people will be able to control the dosage rate, and administrating injections on their own. It will enable patients to control their drugs and also protect the healthcare workers at the same time. According to World Health Organization, approximate 2 million healthcare workers experience transdermal exposure to infectious disease. They further state that 37.6% Hepatitis B and 4.4% of HIV or AIDS infections are caused due to needle stick injuries worldwide.
Global Patient-Controlled Injectors Market: Growth Drivers and Challenges
Growth Drivers
-
Rise in Chronic Conditions Frequency
According to the Centers for Disease control and prevention (CDC), 129 million civilian people suffered from one chronic disease in 2018.
The rising cases of chronic illness will lead to the sales of Patient-Controlled Injectors in the market. Lack of physical activity, and consumption of alcohol give rise to the diseases like diabetes, obesity and sometimes cancer. This rate is increasing at a very rapid rate due to people negligence of people over their physical health and the daily lifestyle.
-
Rising Patient Preference for Patient-controlled Injectors
According to National Library of Medicine, time saving was the important reason for increasing preference for OBI among patients.
-
Rising Prevalence of Cancer
According to Centers of Disease Control and Prevention more than a million cancer cases were diagnosed in the US in 2020.
-
Impact of Covid19 on Visit for Medical Care
According to Centers of Disease Control and Prevention, in their study stated that 32% of US adults avoided the routine medical care due to the rising risk of covid19.
-
More Safe and Efficacious Among Patients
Use of the one press patient-controlled injector was more efficacious and well tolerated among moderate to severe psoriasis patient.
Challenges
-
Distribution Channels disrupted by Physical Distancing Policy
-
Extravagant Cost of Patient-Controlled Injectors
-
Time-Consuming approvals process for Launch- The time taken for approvals of patient-controlled injectors is longer owing to stringent regulatory norms, this challenges the market’s growth.
The demand for patient-controlled injectors increased during the outburst of covid19 virus. Though there was positive impact on the growth of the market, physical distancing policy acted as biggest barrier to the distribution channel. Supplying the injectors became one of the tedious tasks since some of the markets remained relatively closed.
The patient-controlled injectors market is segmented and analysed for demand and supply by product into electronic wearable injector, mechanical wearable injector, and infusion pumps. Amongst these segments electronic wearable injectors segment is estimated to hold a notable share in the market by the end of the year, 2033. Whereas mechanical wearable injector segment is estimated to hold the largest CAGR in the forecast period owing to the rising demand for mechanical wearable injector, as a result of cost-effective superior treatment. The wearable injectors have small parts which makes it cost efficient. Therefore, the manufacturing cost is comparable to that of typical prefilled, single-use auto-injector. The growing healthcare expenditure is estimated to boost the market growth. According to the World Bank data, 9.83% of the GDP was spent on healthcare services across the globe in 2019.
Global Patient-Controlled Injectors Market Regional Synopsis
Regionally, the global patient-controlled injectors market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2033, backed by rise in risk of chronic disease such as cancer, obesity, opioids usage, increases in alcohol consumption, and others. The frequency of chronic disease has rose to very great extend in North America. According to the National Library of Medicine, 133 million people across U.S which is nearly 45% of population suffer from at least one chronic disease hence Patient-Controlled Injectors are adopted to treat this disease for their ability to provide accurate dose.
Market Segmentation
Our in-depth analysis of the global patient-controlled injectors market includes the following segments
|
By Product |
Electronic Wearable Injector Mechanical Wearable Injector Infusion Pumps |
|
By Application |
Cancer Treatment Auto Immune Treatment Blood Disorder Treatment |
|
By Distribution Channel |
Hospital Pharmacies Retail Pharmacies Mail Order Pharmacies |
Customize this Report: Request Customization
Key Companies Dominating the Global Patient-Controlled Injectors Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global patient-controlled injectors market that are included in our report are West Pharmaceutical Services, Inc., Johnson & Johnson Private Limited, Janssen Pharmaceutical Companies, United Therapeutics Corporation, Westbourne Medical Ltd., SC Pharmaceuticals, Inc., Gerresheimer AG, At F. Hoffmann-La Roche Ltd, Ypsomed AG, and Enable Injections.
Global Patient-Controlled Injector Market: Latest Development
-
June, 2021, United Therapeutics Corporation: First Patient Enrolled in Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis, According to United Therapeutics.
-
October, 2021 Ypsomed AG launches its world’s first auto-injector for already-filled needles with integrity connectivity.
- West Pharmaceutical Services Inc.
- Johnson & Johnson Private Limited
- Janssen Pharmaceutical Companies
- United Therapeutics Corporation
- Westbourne Medical Ltd.
- SC Pharmaceuticals, Inc.
- Gerresheimer AG
- At F. Hoffmann-La Roche Ltd
- Ypsomed AG
- Enable Injections
Related Reports
Proof of Quality & Reliability
